Tetrahydrouridine
- Generic Name
- Tetrahydrouridine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16N2O6
- CAS Number
- 18771-50-1
- Unique Ingredient Identifier
- 0NIZ8H6OL8
- Background
Tetrahydrouridine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Sickle Cell Disease, and Head and Neck Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05816356
- Locations
- 🇺🇸
Worldwide Clinical Trails Early Phase Services, San Antonio, Texas, United States
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Yogen Saunthararajah
- Target Recruit Count
- 7
- Registration Number
- NCT02846935
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Yogen Saunthararajah
- Target Recruit Count
- 13
- Registration Number
- NCT02847000
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
- Conditions
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT02664181
- Locations
- 🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT01041443
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain
- Conditions
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Brian Lally
- Target Recruit Count
- 2
- Registration Number
- NCT00521183
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
- Conditions
- Interventions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 1
- Registration Number
- NCT00077051
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.